On June 19, Gelonhui reported that Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary Jiangsu Tasly Deyi Pharmaceutical Co., Ltd. received the "Drug Application Approval Notice" issued by the National Medical Products Administration for the supplementary application of furmarate ketotifen tablets, which approved the consistency evaluation of the quality and efficacy of generic drugs. Furmarate ketotifen tablets are used for allergic rhinitis and allergic asthma and are a class B drug in the "National basic medical insurance, work-related injury insurance and maternity insurance drug list (2023)."
天士力(600535.SH)：富马酸酮替芬片通过仿制药一致性评价
Tasly Pharmaceutical Group (600535.SH): The Ketoprofen Sustained-Release Tablets passed the generic consistency evaluation of the drug.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.